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In 1956, Keettel, Pixley and Elkins proposed cytologic 
examination of intraoperative peritoneal washings as a means of 
detecting subclinical metastases. Subsequently, peritoneal washing 
cytology (hereafter referred to as "peritoneal cytology") has been 
adopted as part of the surgical work-up of such patients. In 1971, 
Creasman and Rutledge reported that peritoneal cytologic results 
correlated well with prognosis in ovarian, endometrial, and cervical 
cancer. In 1986 this concept was incorporated into the official staging of 
Ovarian Cancer by International federation of Gynaecology and 
Obstetrics Peritoneal Fluid Cytology used for Diagnosis which can be 
prospective or for confirmation and Staging of tumors. PFC can be done 
from Ascites/effusions - used for diagnostic purpose Washings/lavage - 
staging of tumors. Both types can be used for ancillary investigations 
and molecular studies 
Positive cytology usually from ovary, tube or peritoneum. 
Endometrial carcinoma rare. As good as tissue biopsy diagnosis and 
better than random biopsies, but not as good as a decent omental 
biopsy. PFC can be acceptable as tissue diagnosis if cell blocks can be 
prepared. Often first investigation (triage patients accordingly). Need to 
establish carcinoma. Non-epithelial malignant cells can be present but 
more difficult to pick up. Correlate with radiological and clinical 
parameters as well as serology. Re-accumulated fluid is often a better 
sample for diagnosis. Cytological examination of peritoneal washings 
taken during surgery enables the initial as well as the second look 
clinical staging of the ovarian carcinoma and influences the prognosis of 
the disease, further management and response to therapy. The 
sensitivity and specificity of cytological analysis depends on the quality 
of the sample, histological type of the tumor and the stage of the 
disease. 
 
PFC in Diagnosis of Gynaecological Cancers  
 Dual population  
 Single cells, sometimes similar in size to mesothelial cells  
 Cell blocks and double immunostaining techniques enhance value  
 Belfast preparations often equally good  
 Main issue is source of malignant cells outside of the female genital 
tract. Hence, immunocytochemistry required.  
 
 
PFC in Ovarian (+ Tubal/Peritoneal) Carcinoma  
 3D/papillary clusters or proliferation spheres  
 Grouped as acini/glands or Indian file 
 Vacuolation (can be targetoid) 
 Psammoma bodies 
 Pleomorphism  
 
Fig 1: Showing peritoneal cytology in case of Ovarian Carcinoma. 
 
PFC in Endometrial Carcinoma  
• Grouped as acini/glands 
• 3D/papillary clusters 
• Can be vacuolated (clear cell carcinoma)  
 
PFC in Gynaecological Cancers Pitfalls  
 Psammoma bodies associated with benign conditions  
 Ciliary tuft sex foliating from fimbrial ends of tubes  
 Degenerative changes mimicking malignancy  
 Exfoliation from endosalpingiosis, endometriosis and mesothelial 
hyperplasia ± degeneration  
 Exfoliation from serous borderline tumours (can be overcalled as 
malignant if histology not available) 
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 Exfoliation of other cells such as Mullerian rests. More common with 
washings  
 Artefactual contamination by malignant cells during sampling  
 Immunocytochemistry less reliable in washings  
 Other adenocarcinomas need to be distinguished requiring a large 
panel of antibodies  
 Reactive mesothelial cells  
 
PFC in Gynaecological Cancers Immunocyto/histochemistry  
 Possible in Belfast preparations  
 Ideally on cell blocks  
 Useful when no or vague dual population  
 Useful when no clinical/radiological findings  
 Useful to distinguish mesothelial from carcinoma cells  
 A small robust panel required  
 Best to use in conjunction with radiological, clinical and serological 
parameters. 
 
Antibodies used are: 
BerEp4 (other epithelial markers, e.g. MOC-31)  
CK7, 20  
CEA, CDX2, WT1, PAX8, SMO47  
TTF, GCDFP15, mammaglobin  
CK5-6, thrombomodullin, calretinin  
Rab25  
Ki 67  
MUC4  
Claudin 1, 3, 7  
 
 1988 FIGO staging for ovarian cancers requires PFC analysis (1C and 
2C) - ovarian carcinoma diagnosis already known. BerEp4 may be the 
only immunostain required. 
 2009 FIGO staging for endometrial cancers does not require PFC 
analysis  
• Useful to record findings in histology reports if possible  
 
PFC in Staging Endometrial Cancers  
 Positive PFC - ?significance in Stage 1 & 2 malignancies  
 Poor prognosis cancers usually have positive PFC  
 Artefactual seeding of cells by hysteroscopy or LAVH with intrauterine 
balloon manipulation  
 ICCR have ‘recommended’ that PFC findings be recorded, if available.  
 Recent Advances in Ovarian Cancer PFC  
 Diagnostic markers  
 CD4+/IL-17 overexpressed in ovarian carcinoma cells  
 Scavenger receptor class A, member 3(SCARA 3) raised in ovarian 
cancer (> breast cancer)  
• Prognostic markers  
 Adhesion molecule protein signatures  
 EpCAM +ve microparticles are shed from ovarian carcinoma cells and 
promote migration (?implants in SBTs)  
 Osteopontin (if raised, prognosis is good) • Therapeutic target 
markers  
 HMGA protein expression (serous carcinoma) - Androgen receptor 
expression  
• Comparative genomic hybridisation (CGH)  
 allows genome wide analysis (e.g. a gain of 8q24.1 predicts poor 
prognosis and advanced disease)  
 tumour specific hypermethylation of BRCA-1 and RAS may allow 
early detection of ovarian cancer  
 
2. Method 
Peritoneal fluid was examined for the presence of tumor cells 
in 94 patients with ovarian and endometrial cancer. The findings were 
correlated with the type, grade, and stage of the tumor. Fluids that were 
positive for malignant cells were associated with serous and 
endometrioid carcinomas of ovary more often than with carcinomas of 
other types. Patients with high-stage tumors of all types had positive 
fluids more often than those with low-stage tumors. The presence of 
tumor cells in the fluid indicated a worse prognosis at 2 years. Analysis 
of other factors that influence prognosis, however, revealed that this 
difference was related more specifically to the stage of the disease. 
Since the presence of tumor cells in abdominal fluid is a factor in the 
subclassification of Stage I and Stage II ovarian cancer, analysis of a 
larger group of patients with tumors in these stages is needed to 
establish the prognostic significance of positive cytological findings 
independent of other prognostic factors. 
 
3. Conclusion 
PFC is powerful tool when utilised in conjunction with 
clinical, serological and radiological parameters, PFC is as good as tissue 
biopsy diagnosis, Robust panel of antibodies required for diagnosis and 
subtyping, Document PFC findings in histology reports if possible, PFC 
allows molecular and genomic studies to indicate prognosis and 
therapeutic strategies as well as discovery of novel immunomarkers  
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